Clinical Trial Update: TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tumor-infiltrating lymphocytes (TILs) and low-dose IL-2 after cyclophosphamide and fludarabine in pleural mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Mesothelioma

Drugs mentioned

• Interleukin-2 (low-dose) (interleukin-2)
• TILs

Snippet

Sponsor: University Health Network, Toronto | Conditions: Pleural Mesothelioma | Phase 1, Phase 2 | Status: COMPLETED